| Date | Title | | | 12/18/08 | Pfizer and Celldex Therapeutics Announce Amendment to ACT III Study of CDX-110 in Glioblastoma Multiforme| NEEDHAM, Mass. and NEW YORK, Dec. 18 /PRNewswire-FirstCall/ -- Celldex
Therapeutics (Nasdaq: CLDX) and Pfizer Inc. (NYSE: PFE) today announced plans
to amend the ongoing ACT III clinical trial involving the investigational
compound, CDX-110. ACT III is a randomized open-label, two-arm, Phase 2b/3
trial comparing CDX-110 combined with temozolomide to temozolomide alone in
patients with newly diagnosed Glioblastoma Multiforme (GBM). Only the Phase
2b portion of the trial has been open ... |
|  | | 11/11/08 | Celldex Announces Licensing Agreement for Novel Cancer Antibody Program| NEEDHAM, Mass.--(BUSINESS WIRE)--Nov. 11, 2008--Celldex
Therapeutics, Inc. (Nasdaq: CLDX) today announced that it has entered
into an Exclusive Patent and Know-How License Agreement with the
University of Southampton, UK, to develop human antibodies towards
CD27, a potentially important target for immunotherapy of various
cancers. In pre-clinical models, antibodies to CD27 have been shown to
mediate anti-tumor effects alone, and may be particularly effective in
combination with other ... |
| | | 11/05/08 | Celldex Reports Third Quarter and Nine Month Financial Results| - Conference Call Wednesday, November 5, at 9:00 a.m. Eastern Time
-
NEEDHAM, Mass.--(BUSINESS WIRE)--Nov. 5, 2008--Celldex
Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for
the third quarter and nine-month period ended September 30, 2008.
Celldex reported a net loss of $7.7 million, or $0.49 per share, for
the third quarter of 2008 compared to a net loss of $4.1 million, or
$0.49 per share, for the third quarter of 2007. For... |
| | | 10/31/08 | Celldex Presents Results from Phase 1 Studies of CDX-1307 with GM-CSF| --CDX-1307 well tolerated with good immune responses observed--
NEEDHAM, Mass.--(BUSINESS WIRE)--Oct. 31, 2008--Celldex
Therapeutics, Inc. (NASDAQ: CLDX) announced initial results from
multi-center Phase 1 clinical trials of its cancer vaccine candidate,
CDX-1307, combined with GM-CSF, at the International Society for the
Biologic Therapy of Cancer (iSBTc) annual meeting in San Diego. These
data provide the basis for the ongoing assessment of CDX-1307 combined
with more potent adj... |
| |
|
